Thursday, January 17, 2013
Publication and contact
antibody-toxin fusion immunotoxins in algae
In vitro and mouse studies suggest algae chloroplasts could
be used to produce anticancer immunotoxin fusion proteins. Genetically
engineered green algae chloroplasts were used to produce an immunotoxin
fusion protein that combined a eukaryotic endotoxin and an antibody domain
targeting B cell-specific CD22. The algae-produced
immunotoxin-induced death of human B cell lymphoma cells but not normal human
B or T cells. In a mouse xenograft model of human lymphoma, the
algae-produced immunotoxins inhibited tumor progression and increased
survival compared with the antibody domain alone. Next steps include
designing a new fusion protein for testing in large animal models.
At least six companies have antibodies targeting CD22 in Phase II testing or
earlier to treat various cancers.
Published online Jan. 17, 2013
Patent application filed;
licensed to Sapphire Energy Inc., a biofuels
Tran, M. et al. Proc.
Natl. Acad. Sci. USA; published online
Dec. 10, 2012;
Contact: Stephen P. Mayfield, University of California, San
Diego, La Jolla, Calif.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]